Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTEDTravere Therapeutics, Inc. Analyst EPS Estimates
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2025 | 6 | -$0.70 | -$0.44 | -$0.57 |
| Q2 2025 | 8 | -$3.43 | $3.20 | -$0.31 |
| Q3 2025 | 7 | -$0.52 | -$0.10 | -$0.30 |
| Q4 2025 | 7 | -$0.70 | $0.63 | -$0.07 |
| Q1 2026 | 5 | -$0.24 | $0.06 | -$0.11 |
| Q2 2026 | 1 | $0.03 | $0.04 | $0.03 |
| Q3 2026 | 1 | $0.14 | $0.20 | $0.17 |
| Q4 2026 | 1 | $0.51 | $0.73 | $0.61 |
Travere Therapeutics, Inc. Earnings Date And Information
Travere Therapeutics, Inc. last posted its earnings results on Thursday, October 30th, 2025. The company reported $0.28 earnings per share for the quarter, topping analysts' consensus estimates of $-0.31 by $0.59. The company had revenue of 164.86 M for the quarter and had revenue of 233.18 M for the year. Travere Therapeutics, Inc. has generated $-4 earnings per share over the last year ($-4.08 diluted earnings per share) and currently has a price-to-earnings ratio of -35.27. Travere Therapeutics, Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, November 6th, 2025 based on prior year's report dates.
Travere Therapeutics, Inc. Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 10/30/2025 | Q3 2025 | -$0.31 | $0.29 | 0.6 | $105.21 M | $164.86 M |
| 08/06/2025 | Q2 2025 | -$0.28 | -$0.14 | 0.14 | $99.47 M | $114.45 M |
| 05/01/2025 | Q1 2025 | -$0.55 | -$0.47 | 0.08 | N/A | $81.73 M |
| 02/20/2025 | Q4 2024 | N/A | -$0.73 | N/A | N/A | $74.79 M |
| 10/31/2024 | Q3 2024 | -$0.70 | -$0.70 | 0 | $60.87 M | $62.90 M |
| 08/01/2024 | Q2 2024 | -$0.87 | -$0.91 | -0.04 | $50.40 M | $54.12 M |
| 05/06/2024 | Q1 2024 | -$0.98 | -$1.76 | -0.78 | N/A | $41.37 M |
| 02/20/2024 | Q4 2023 | N/A | -$1.18 | N/A | N/A | $45.06 M |
| 11/07/2023 | Q3 2023 | -$1.09 | -$0.99 | 0.1 | $57.33 M | $37.10 M |
| 08/03/2023 | Q2 2023 | -$1.16 | -$1.13 | 0.03 | $53.56 M | $32.20 M |
| 05/04/2023 | Q1 2023 | -$1.18 | -$1.27 | -0.09 | $50.61 M | $56.99 M |
| 02/23/2023 | Q4 2022 | -$1.04 | -$1.03 | 0.01 | $53.01 M | $55.87 M |
| 10/27/2022 | Q3 2022 | -$0.97 | -$1.09 | -0.12 | $54.12 M | $53.50 M |
| 08/04/2022 | Q2 2022 | -$0.94 | -$1.05 | -0.11 | $49.63 M | $54.17 M |
| 05/05/2022 | Q1 2022 | -$0.85 | -$1.20 | -0.35 | $52.19 M | $48.49 M |
| 02/24/2022 | Q4 2021 | -$0.72 | -$0.84 | -0.12 | $57.80 M | $57.25 M |
| 10/28/2021 | Q3 2021 | N/A | -$0.59 | N/A | $60.93 M | $68.22 M |
| 07/29/2021 | Q2 2021 | -$0.73 | -$0.64 | 0.09 | $50.33 M | $54.62 M |
| 05/06/2021 | Q1 2021 | -$0.56 | -$0.96 | -0.4 | $50.09 M | $47.41 M |
| 03/01/2021 | Q4 2020 | -$0.43 | -$2.37 | -1.94 | $51.66 M | $50.98 M |
Explore Related Stocks for Market Trends
Explore our related stocks for the latest market trends and stock news to stay informed and make better decisions.
Travere Therapeutics, Inc. Earnings: FAQ's
Travere Therapeutics, Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, November 6th, 2025 based offlast year's report dates.
In the previous quarter, Travere Therapeutics, Inc. (:TVTX) reported $0.28 earnings per share (EPS) to beat the analysts' consensus estimate of $-0.31 by $0.59.
The conference call for Travere Therapeutics, Inc.'s latest earnings report can be listened to online.
The conference call transcript for Travere Therapeutics, Inc.'s latest earnings report can be read online.
Travere Therapeutics, Inc. (:TVTX) has a recorded annual revenue of $233.18 M.
Travere Therapeutics, Inc. (:TVTX) has a recorded net income of $-321,545,000.Travere Therapeutics, Inc. has generated $-4.08 earnings per share over the last four quarters.
Travere Therapeutics, Inc. (:TVTX) has a price-to-earnings ratio of -35.27 and price/earnings-to-growth ratio is -0.73.